Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best–worst scaling

References

• Orphanet: Prader Willi syndrome [Internet]. Paris, France; 2007. Available at: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=739 [Last accessed 31 August 2018]
   Google Scholar
• Goldstone AP, Aronne LJ. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2003;15:12-20
   Web of Science ®Google Scholar
• Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3-13
   PubMed Web of Science ®Google Scholar
• Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 2015;38:1249-63
   PubMed Web of Science ®Google Scholar
• Griggs JL, Sinnayah P, Mathai ML. Prader–Willi syndrome: from genetics to behaviour, with special focus on appetite treatments. Neurosci Biobehav Rev 2015;59:155-72
   PubMed Web of Science ®Google Scholar
• Cohen M, Hamilton J, Narang I. Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi syndrome. PLoS One 2014;9:e101012
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Linertová R, Oliva-Moreno J, et al. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Eur J Heal Econ 2016;17:99-108
   PubMed Web of Science ®Google Scholar
• Chevreul K, Berg Brigham K, Clément M-C, et al. Economic burden and health-related quality of life associated with Prader-Willi syndrome in France. J Intellect Disabil Res 2016;60:879-90
   PubMed Web of Science ®Google Scholar
• Dykens EM, Maxwell MA, Pantino E, et al. Assessment of hyperphagia in Prader-Willi syndrome. Obesity 2007;15:1816-26
   PubMed Web of Science ®Google Scholar
• Goldstone AP, Holland AJ, Butler J V, et al. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes 2012;36:1564-70
   Web of Science ®Google Scholar
• Miller J, Strong T, Heinemann J. Medication trials for hyperphagia and food-related behaviors in Prader–Willi syndrome. Diseases 2015;3:78-85
   PubMedGoogle Scholar
• Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97
   PubMed Web of Science ®Google Scholar
• Cassidy SB, Schwartz S, Miller JL, et al. Prader-Willi syndrome. Genet Med 2012;14:10-26
   PubMed Web of Science ®Google Scholar
• Butler MG, Thompson T. Prader-Willi syndrome: clinical and genetic findings. Endocrinologist 2000;10:3S-16S
   PubMed Web of Science ®Google Scholar
• Prader-Willi Syndrome Association (USA). Summary of active clinical trials for Prader-Willi syndrome hyperphagia [Internet]. Sarasota, FL; c2016. Available at: https://www.pwsausa.org/summary-active-clinical-trials-prader-willi-syndrome-hyperphagia/ [Last accessed 31 August 2018]
   Google Scholar
• McCandless SE, Yanovski JA, Miller J, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2017;19:1751-61
   PubMed Web of Science ®Google Scholar
• Scheimann A, Butler M, Gourash L, et al. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2008;46:80-3
   PubMed Web of Science ®Google Scholar
• PWS Clinical Trials Consortium [Internet]. c2016. Available at: https://www.pwsctc.org/ [Last accessed 4 May 2017]
   Google Scholar
• Foundation for Prader-Willi Research [Internet]. Walnut, CA, USA; c2018. Available at: https://www.fpwr.org/ [Last accessed 14 April 2017]
   Google Scholar
• Theresa S. PWS Patient Voices [Internet]. Walnut, CA, USA: Foundation for Prader-Willi Research; 2014. Available at: https://www.fpwr.org/wp-content/uploads/2014/04/PatientVoices_presentationWebinarFinal.pdf [Last accessed 10 July 2018]
   Google Scholar
• Flynn TN, Louviere JJ, Peters TJ, et al. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ 2007;26:171-89
   PubMed Web of Science ®Google Scholar
• Janssen EM, Segal JB, Bridges JFP. A framework for instrument development of a choice experiment: an application to type 2 diabetes. Patient 2016;9:465-79
   PubMedGoogle Scholar
• Patient Preference Information – Voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring, MD, USA: U.S. Department of Health and Human Services, Food and Drug Administration; 2016
   Google Scholar
• Perfetto EM, Burke L, Oehrlein EM, et al. Patient-focused drug development: a new direction for collaboration. Med Care 2015;53:9-17
   PubMed Web of Science ®Google Scholar
• Tsai J-H, Janssen E, Bridges J. Research as an event: a novel approach to promote patient-focused drug development. Patient Prefer Adherence 2018;12:673-9
   PubMed Web of Science ®Google Scholar
• Peay HL, Hollin I, Fischer R, et al. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for duchenne muscular dystrophy. Clin Ther 2014;36:624-37
   PubMed Web of Science ®Google Scholar
• Hollin IL, Young C, Hanson C, et al. Developing a patient-centered benefit-risk survey: a community-engaged process. Value Heal 2016;19:751-7
   PubMed Web of Science ®Google Scholar
• Severin F, Schmidtke J, Mühlbacher A, et al. Eliciting preferences for priority setting in genetic testing: a pilot study comparing best-worst scaling and discrete-choice experiments. Eur J Hum Genet 2013;1202-8
   PubMed Web of Science ®Google Scholar
• van Dijk JD, Groothuis-Oudshoorn CGM, Marshall DA, et al. An empirical comparison of discrete choice experiment and best-worst scaling to estimate stakeholders’ risk tolerance for hip replacement surgery. Value Heal 2016;19:316-22
   PubMed Web of Science ®Google Scholar
• Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ 2017;26(12):e1–e16
   Web of Science ®Google Scholar
• Kuhfeld WF. Marketing research methods in SAS. Cary, NC, USA: SAS Institute Inc.; 2010. Available at: https://support.sas.com/techsup/technote/mr2010.pdf [Last accessed 9 March 2017]
   Google Scholar
• DeMuro CJ, Lewis SA, DiBenedetti DB, et al. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res 2012;12:181-7
   PubMed Web of Science ®Google Scholar
• Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A 2011;155A:1040-9
   PubMed Web of Science ®Google Scholar
• Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci 2013;15:398-405
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. Qualitative research in psychology using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101
   Google Scholar
• Louviere JJ, Flynn TN, Marley AAJ. Best-worst scaling: theory, methods and applications. Cambridge: Cambridge University Press; 2015
   Google Scholar
• Wand MP, Jones MC. Kernel smoothing. Boca Raton, FL, USA: Chapman & Hall/CRC; 1995
   Google Scholar
• Janssen EM, Benz HL, Tsai J-H, et al. Identifying and prioritizing concerns associated with prosthetic devices for use in a benefit-risk assessment: a mixed-methods approach. Expert Rev Med Devices 2018;15:385-98
   PubMed Web of Science ®Google Scholar
• Key AP, Dykens EM. Eye tracking as a marker of hyperphagia in Prader-Willi syndrome. Dev Neuropsychol 2018;43:152-61
   PubMed Web of Science ®Google Scholar
• Mullins CD, Vandigo J, Zheng Z, et al. Patient-centeredness in the design of clinical trials. Value Heal 2014;17:471-5
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Aguarón A, Avendaño-Solá C, et al. Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence 2016;10:631-40
   PubMedGoogle Scholar
• Dykens EM, Roof E. Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatry 2008;49:1001-8
   PubMed Web of Science ®Google Scholar
• Murphy JJ, Allen PG, Stevens TH, et al. A meta-analysis of hypothetical bias in stated preference valuation. Environ Resour Econ 2005;30:313-25
   Web of Science ®Google Scholar
• Loomis J. What’s to know about hypothetical bias in stated preference valuation studies? J Econ Surv 2011;25:363-70
   Web of Science ®Google Scholar
• Bridges JF, Wu AW, Jodi Segal F, et al. White paper #1: Stated-preference methods Baltimore, MD, USA: The Johns Hopkins Bloomberg School of Public Health; 2014
   Google Scholar
• Pituch KA, Green VA, Didden R, et al. Parent reported treatment priorities for children with autism spectrum disorders. Res Autism Spectr Disord 2011;5:135-43
   Web of Science ®Google Scholar
• Medical Device Innovation Consortium. Medical Device Innovation Consortium (MDIC) Patient Centered Benefit-Risk Project (PCBR) Appendix A: catalog of methods for assessing patient preferences for benefits and harms of medical technologies. Arlington, VA, USA: Medical Device Innovation Consortium; 2015
   Google Scholar